OPKO Health, Inc. reported first‑quarter 2026 results that fell short of consensus revenue expectations but delivered earnings per share in line with analysts. Total revenue was $124.2 million, a decline of roughly 4.8% from the $130.6 million consensus range of $130.51 million to $130.8 million. Net loss widened to $54.8 million, and earnings per share were –$0.07, matching the consensus estimate of –$0.07.
The revenue shortfall was driven primarily by a contraction in the diagnostics segment, where the sale of BioReference assets and a shift away from high‑margin oncology tests reduced top‑line growth. In contrast, the pharmaceutical segment grew 10.4% year‑over‑year, supported by increased sales and a profit share from NGENLA. The diagnostics decline was compounded by lower reimbursement rates and the exit of certain high‑priced, low‑margin test offerings, while the pharma gains reflected stronger demand for the company’s pipeline products and international expansion.
Gross margin expanded to 36.9% from 28.4% in the prior year, reflecting a favorable mix shift toward higher‑margin pharmaceutical sales and reduced cost of revenue in diagnostics. The margin improvement offset the revenue decline, helping to keep the net loss within analyst expectations. Cash and cash equivalents stood at $341 million, providing a solid liquidity cushion as the company continues to invest in its ModeX Therapeutics pipeline and cost‑control initiatives.
Management reiterated its guidance for the second quarter, projecting revenue of $127 million to $132 million and maintaining a full‑year outlook of $530 million to $560 million. The guidance signals confidence that the company’s restructuring of diagnostics and the growth of its pharmaceutical portfolio will stabilize earnings. The company also reaffirmed its operating cash‑flow and margin targets, underscoring its commitment to disciplined cost management.
In aftermarket trading, the stock fell 0.83% to $1.19, a reaction largely driven by the revenue miss and the persistence of net losses. Investors expressed concern over the company’s cash burn, despite the sizable cash balance. Headwinds include the divestiture of oncology accounts and lower reimbursement rates, while tailwinds are the pharmaceutical segment’s growth, international operations, and progress in the ModeX pipeline, which together suggest a gradual recovery in profitability.
Management emphasized that the diagnostics business is on track to breakeven by mid‑year, thanks to the restructuring of test offerings and the pursuit of double‑digit growth in 4Kscore volumes pending Medicare coverage updates. The company also highlighted ongoing development of its ModeX Therapeutics platform, with several programs in clinical trials, and the collaboration with Entera Bio on an oral long‑acting PTH tablet, positioning OPKO for future revenue diversification and margin improvement.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.